The FDA has FDA cleared Masimo Corp's (NASDAQ: MASI) SedLine brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG Sensor. SedLine helps clinicians monitor ...
Normally, chasing rainbows is an inherently futile act. Masimo’s pursuit, however, is the rare one proven fruitful, with a new CE mark for its Rainbow SuperSensor. The single-use, adhesive SuperSensor ...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the FDA clearance of SedLine ® brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG ...
Zacks.com on MSN
Here's Why You Should Retain Masimo Stock in Your Portfolio Now
MASI's strong Q3 2025 results, FDA clearance and partnerships fuel growth hopes, but SET dependence and reimbursement risks ...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking and release of RD rainbow Lite SET™ sensors, which enable the monitoring of Masimo Oxygen Reserve Index™ ...
Irvine, California-based Masimo, makers of a suite of non-invasive patient monitoring devices and sensors, has expanded the capabilities of its connected platform to allow physicians to view more data ...
When a patient is receiving supplemental oxygen during surgery, there’s a risk that they’ll develop hyperoxia, where their arterial blood becomes oxygenated above normal levels, potentially leading to ...
(RTTNews) - Masimo (MASI) said that the U.S. FDA has cleared SedLine brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG Sensor. With this clearance, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback